Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC

Video

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the frontline treatment of ALK-positive non–small cell lung cancer (NSCLC).

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the frontline treatment of ALK-positive non—small cell lung cancer (NSCLC).

There are 3 FDA-approved therapies for the treatment of ALK-positive NSCLC—–crizotinib (Xalkori), ceritinib (Zykadia), and alectinib (Alecensa). Brigatinib (Alunbrig), though not yet FDA approved, is recommended as a category 1 therapy by the NCCN. Of the approved agents, Liu recommends starting a patient on alectinib.

If brigatinib is FDA approved, choosing between alectinib and brigatinib will be more challenging. In that case, insurance coverage and cost may play more of a role in therapy selection, says Liu. The 2 agents also have slightly different toxicity profiles, so physicians can tailor the toxicity profile towards individual patients. As the data mature between the ALEX trial and the ALTA-1L trials, it will give physicians a better idea of which drug to pursue. The biggest factor that will likely influence physicians is the difference in resistance, Liu concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,